SSTR4: A Potential Drug Target for Cancer, Obesity and Diabetes

Target Name: SSTR4

NCBI ID: G6754

SSTR4

Other Name(s): Somatostatin receptor type 4 | SS-4-R | Somatostatin receptor 4 | G-protein coupled receptor | SS4-R | SS4R | SSR4_HUMAN | somatostatin receptor 4 | Sst4 | SST4 | Somatostatin SRIF2B (SS4R) receptor

SSTR4: A Potential Drug Target for Cancer, Obesity and Diabetes

Somatostatin, a protein produced by the body, plays a critical role in regulating various physiological processes. It is a potent hormone that helps control the growth, development, and maintenance of tissues, including muscles, bones, and organs. Somatostatin has been identified as a potential drug target and a biomarker for various diseases, including cancer, obesity, and diabetes.

SSTR4, the somatostatin receptor type 4, is a transmembrane protein that is expressed in various tissues, including muscle, bone, liver, and pancreas. It is a G protein-coupled receptor (GPCR) that is involved in the signaling pathway of somatostatin. SSTR4 is a promising drug target because of its unique structure and its potential to modulate various physiological processes.

The SSTR4 protein is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is involved in the formation of SSTR4-conjugated receptors, which are involved in the signaling pathway of somatostatin. The transmembrane domain is responsible for the transmembrane transportation of SSTR4 and is involved in the interaction with somatostatin. The intracellular domain is involved in the signaling pathway of SSTR4 and is involved in the regulation of various physiological processes.

SSTR4 is involved in the regulation of cellular processes that are critical for the development and maintenance of tissues, including muscle and bone growth and development. It is also involved in the regulation of cellular processes that are related to the development and maintenance of tissues, such as cell survival and apoptosis.

SSTR4 has been identified as a potential drug target for various diseases, including cancer, obesity, and diabetes. For example, SSTR4 has been shown to be involved in the regulation of cancer cell growth and survival. Researchers have found that SSTR4 is involved in the regulation of cell proliferation and have shown that inhibition of SSTR4 can lead to the inhibition of cancer cell growth.

SSTR4 has also been shown to be involved in the regulation of obesity and diabetes. Researchers have found that SSTR4 is involved in the regulation of body weight and have shown that inhibition of SSTR4 can lead to the regulation of body weight. SSTR4 has also been shown to be involved in the regulation of insulin sensitivity and have shown that inhibition of SSTR4 can lead to the regulation of insulin sensitivity.

In conclusion, SSTR4 is a promising drug target and a biomarker for various diseases, including cancer, obesity, and diabetes. Its unique structure and its potential to modulate various physiological processes make it an attractive target for drug development. Further research is needed to fully understand the role of SSTR4 in the regulation of various physiological processes and to develop effective treatments for diseases associated with SSTR4 dysfunction.

Protein Name: Somatostatin Receptor 4

Functions: Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. It is functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade. Mediates antiproliferative action of somatostatin in tumor cells

The "SSTR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSTR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets